KEYNOTE001 (39 in C, 510 in F). P010 A Phase 30 KEYNOTE010 is II/III 920 days 2015 an ongoing for pts; and randomised of Two study trial of Doses of al pembrolizumab 170 MK-3475 PDL1 two doses (2 pts mg/kg Q3W or versus level 10 mg/kg Q3W) Docetaxel in = versus Previously docetaxel 75 Treated mg/m2. Subjects Patients were with required to Squamous have had Histology progression on Non-Small or after prior Cell Lung platinum-based Cancer; chemotherapy. Phase II/III Cases are included for patients who had at least one dose of pembrolizumab. Approximately 323 NSCLC patients had been treated in KEYNOTE010. are ongoing NSCLC studies in Japan using a range of doses. A total of 40 patients have been enrolled to date. P021 A Phase I/II Open May 2016 Study of 320 al pts; in 1 pts Combination with or in Patients with Locally Advanced or
KEYNOTE001 (39 in C, 510 in F). P010 A Phase II/III of Two Doses of MK-3475 versus Docetaxel in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer; Phase II/III for study PDL1 level = 920 pts; 170 pts 30 days and 2015 KEYNOTE010 is an ongoing randomised trial of pembrolizumab two doses (2 mg/kg Q3W or 10 mg/kg Q3W) versus docetaxel 75 mg/m2. Patients were required to have had progression on or after prior platinum-based chemotherapy. Cases are included for patients who had at least one dose of pembrolizumab. Approximately 323 NSCLC patients had been treated in KEYNOTE010. are ongoing NSCLC studies in Japan using a range of doses. A total of 40 patients have been enrolled to date. P021 A Phase I/II Study of in Combination with or in Patients with Locally Advanced or Open 320 pts; 1 pts May 2016 al al
auspar-pembrolizumab-rch-161014.docx